Homology Medicines, Inc.

Homology Medicines Declares Distribution to Common Stockholders

HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX

HOMOLOGY MEDICINES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX

Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX

FIXX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Homology Medicines, Inc. Is Fair to Shareholders

Q32 Bio and Homology Medicines Announce Merger Agreement

Q32 Bio and Homology Medicines Announce Merger Agreement

Homology Medicines Reports Third Quarter 2023 Financial Results

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Homology Medicines, Inc. (NASDAQ: FIXX) and Encourages Long-Term Investors to Contact the Firm - FIXX

Best Penny Stocks To Buy? 6 To Watch Before Next Week

Penny Stocks To Buy? 3 To Watch While The Stock Market Is Down

Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU

Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates

Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates

5 Penny Stocks To Buy According To Analysts, Targets Up To 1,050%

Homology Medicines (FIXX) Reports Q2 Loss, Lags Revenue Estimates

Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU

DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Homology Medicines, Inc. (FIXX) Shareholders of Class Action Last Few Hours to Actively Participate

HOMOLOGY DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Homology Medicines, Inc. and Encourages Investors to Contact the Firm